Diabetes and Restenosis

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2022 Feb 15

PMID 35164744

Authors

Scott Wilson

Pasquale Mone

Urna Kansakar

Stanislovas S Jankauskas

Kwame Donkor

Ayobami Adebayo

Fahimeh Varzideh

Michael Eacobacci

Jessica Gambardella

Angela Lombardi

Gaetano Santulli

Affiliations

Soon will be listed here.

Abstract

Restenosis, defined as the re-narrowing of an arterial lumen after revascularization, represents an increasingly important issue in clinical practice. Indeed, as the number of stent placements has risen to an estimate that exceeds 3 million annually worldwide, revascularization procedures have become much more common. Several investigators have demonstrated that vessels in patients with diabetes mellitus have an increased risk restenosis. Here we present a systematic overview of the effects of diabetes on in-stent restenosis. Current classification and updated epidemiology of restenosis are discussed, alongside the main mechanisms underlying the pathophysiology of this event. Then, we summarize the clinical presentation of restenosis, emphasizing the importance of glycemic control in diabetic patients. Indeed, in diabetic patients who underwent revascularization procedures a proper glycemic control remains imperative.

Citing Articles

Risk Factors and Incidence for In-Stent Restenosis with Drug-Eluting Stent: A Systematic Review and Meta-Analysis.

Liu B, Li M, Liu J, Xie L, Li J, Liu Y Rev Cardiovasc Med. 2025; 25(12):458.

PMID: 39742219 PMC: 11683691. DOI: 10.31083/j.rcm2512458.

Extended Review and Updates of Nonalcoholic Fatty Pancreas Disease.

Habas E, Farfar K, Habas E, Rayani A, Elzouki A Saudi J Med Med Sci. 2024; 12(4):284-291.

PMID: 39539795 PMC: 11556510. DOI: 10.4103/sjmms.sjmms_526_23.

Metabolomics revealed pharmacodynamic effects of aspirin and indobufen in patients after percutaneous transluminal angioplasty surgery.

Sun S, Xun K, Li D, Bao R Front Cardiovasc Med. 2024; 11:1433643.

PMID: 39534497 PMC: 11554490. DOI: 10.3389/fcvm.2024.1433643.

Assessment of Risk Factors for Coronary Artery Disease and Severity by Coronary Computed Tomography Angiography Imaging.

Wu H, Yang G, Zhang S, Luo J, Zhou P, Chen Y Int J Gen Med. 2024; 17:4607-4615.

PMID: 39429962 PMC: 11488507. DOI: 10.2147/IJGM.S475008.

Mechanisms of ferroptosis and glucagon-like peptide-1 receptor agonist in post-percutaneous coronary intervention restenosis.

Wang M, Wang L, Sun H, Yuan H, Li Y Mol Cell Biochem. 2024; 480(3):1465-1480.

PMID: 39283562 DOI: 10.1007/s11010-024-05118-6.

References

Kim Y, Her A, Jeong M, Kim B, Hong S, Kim S . Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients. Sci Rep. 2021; 11(1):9364. PMC: 8087777. DOI: 10.1038/s41598-021-88593-x. View

Ruiz H, Ramasamy R, Schmidt A . Advanced Glycation End Products: Building on the Concept of the "Common Soil" in Metabolic Disease. Endocrinology. 2019; 161(1). PMC: 7188081. DOI: 10.1210/endocr/bqz006. View

Faries P, Rohan D, Takahara H, Wyers M, Contreras M, Quist W . Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration. J Vasc Surg. 2001; 33(3):601-7. DOI: 10.1067/mva.2001.111806. View

Doshi R, Kumar A, Adalja D, Vaz I, Shariff M . Meta-analysis of Usefulness of Drug Coated Balloon Versus Standard Balloon in the Treatment of Femoropopliteal In-Stent-Restenosis. Am J Cardiol. 2020; 133:170-171. DOI: 10.1016/j.amjcard.2020.07.024. View

. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S144-S174. DOI: 10.2337/dc22-S010. View

Yanaka K, Konishi A, Shinke T, Kozuki A, Kawamori H, Tsukiyama Y . Open-Label Multicenter Registry on the Outcomes of In-Stent Restenosis Treated by Balloon Angioplasty with Optical Frequency Domain Imaging in the Superficial Femoral Artery (ISLAND-SFA Study). Ann Vasc Dis. 2021; 13(3):291-299. PMC: 7751072. DOI: 10.3400/avd.oa.20-00077. View

Corpus R, George P, House J, Dixon S, Ajluni S, Devlin W . Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol. 2004; 43(1):8-14. DOI: 10.1016/j.jacc.2003.06.019. View

Lange R, Hillis L . Second-generation drug-eluting coronary stents. N Engl J Med. 2010; 362(18):1728-30. DOI: 10.1056/NEJMe1001069. View

Texakalidis P, Tzoumas A, Giannopoulos S, Jonnalagadda A, Jabbour P, Rangel-Castilla L . Risk Factors for Restenosis After Carotid Revascularization: A Meta-Analysis of Hazard Ratios. World Neurosurg. 2019; 125:414-424. DOI: 10.1016/j.wneu.2019.02.065. View

10.

Cahn A, Wiviott S, Mosenzon O, Goodrich E, Murphy S, Yanuv I . Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care. 2022; 45(4):938-946. DOI: 10.2337/dc21-1744. View

11.

Alfonso F, Byrne R, Rivero F, Kastrati A . Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014; 63(24):2659-73. DOI: 10.1016/j.jacc.2014.02.545. View

12.

Mone P, Gambardella J, Minicucci F, Lombardi A, Mauro C, Santulli G . Hyperglycemia Drives Stent Restenosis in STEMI Patients. Diabetes Care. 2021; 44(11):e192-e193. PMC: 8546275. DOI: 10.2337/dc21-0939. View

13.

Ribichini F, Ferrero V, Matullo G, Feola M, Vado A, Camilla T . Association study of the I/D polymorphism and plasma angiotensin-converting enzyme (ACE) as risk factors for stent restenosis. Clin Sci (Lond). 2004; 107(4):381-9. DOI: 10.1042/CS20030380. View

14.

Tachkov K, Mitov K, Koleva Y, Mitkova Z, Kamusheva M, Dimitrova M . Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria. PLoS One. 2020; 15(5):e0232815. PMC: 7213739. DOI: 10.1371/journal.pone.0232815. View

15.

Fujita T, Takeda T, Tsujino Y, Yamaji M, Sakaguchi T, Maeda K . Effect of Glycemic Control During Follow-up on Late Target Lesion Revascularization After Implantation of New-Generation Drug-Eluting Stents in Patients With Diabetes　- A Single-Center Observational Study. Circ Rep. 2021; 2(9):479-489. PMC: 7819662. DOI: 10.1253/circrep.CR-20-0065. View

16.

Zhen Y, Ren H, Chen J, Chang Z, Wang C, Zheng J . Systematic Review and Meta-Analysis of Drug-Coated Balloon Angioplasty for In-Stent Restenosis in Femoropopliteal Artery Disease. J Vasc Interv Radiol. 2021; 33(4):368-374.e6. DOI: 10.1016/j.jvir.2021.12.007. View

17.

Honda Y, Muramatsu T, Ito Y, Sakai T, Hirano K, Yamawaki M . Impact of ultra-long second-generation drug-eluting stent implantation. Catheter Cardiovasc Interv. 2015; 87(2):E44-53. DOI: 10.1002/ccd.26010. View

18.

Hong S, Kim M, Ahn T, Ahn Y, Bae J, Shim W . Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart. 2006; 92(8):1119-24. PMC: 1861125. DOI: 10.1136/hrt.2005.075960. View

19.

Watanabe M, Risi R, Camajani E, Contini S, Persichetti A, Tuccinardi D . Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study. Nutrients. 2020; 12(7). PMC: 7400878. DOI: 10.3390/nu12072141. View

20.

Aronson D . Restenosis in diabetic patients: is hyperinsulinemia the culprit?. Circulation. 1996; 94(11):3003-5. View